← Eichor
Study identifier: NCT04858009 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis

Condition: Metastatic Pancreatic Carcinoma · Stage IV Pancreatic Cancer AJCC v8 · Metastatic Malignant Neoplasm in the Peritoneum  ·  Sponsor: Mayo Clinic

PhasePhase 2
Planned participants40
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

This phase II trial studies the effects of hyperthermic intraperitoneal chemotherapy (HIPEC) in treating patients with pancreatic cancer that has spread to the internal abdominal area (peritoneal metastasis). Chemotherapy drugs, such as nab-paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. HIPEC involves "heated" chemotherapy that is placed directly in the abdomen through laparoscopic instruments, instead of through an intravenous injection. This study may help doctors determine how safe and effective HIPEC work in treating patient with pancreatic cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Clinical Trials Referral Office  ·  855-776-0015  ·  mayocliniccancerstudies@mayo.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Mayo Clinic in RochesterRochester, Minnesota, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04858009